• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Vascular smooth muscle cell proliferation in restenosis.

作者信息

Marx Steven O, Totary-Jain Hana, Marks Andrew R

机构信息

Division of Cardiology, Department of Medicine, Wu Center for Molecular Cardiology, Columbia University College of Physicians and Surgeons, New York, NY, USA.

出版信息

Circ Cardiovasc Interv. 2011 Feb 1;4(1):104-11. doi: 10.1161/CIRCINTERVENTIONS.110.957332.

DOI:10.1161/CIRCINTERVENTIONS.110.957332
PMID:21325199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3816546/
Abstract
摘要

相似文献

1
Vascular smooth muscle cell proliferation in restenosis.再狭窄中的血管平滑肌细胞增殖
Circ Cardiovasc Interv. 2011 Feb 1;4(1):104-11. doi: 10.1161/CIRCINTERVENTIONS.110.957332.
2
Cutting balloon combined with paclitaxel-eluting balloon for treatment of in-stent restenosis.切割球囊联合紫杉醇洗脱球囊治疗支架内再狭窄。
Arch Cardiovasc Dis. 2013 Feb;106(2):79-85. doi: 10.1016/j.acvd.2012.10.004. Epub 2013 Jan 30.
3
Molecular mechanisms of in-stent restenosis and approach to therapy with eluting stents.支架内再狭窄的分子机制及洗脱支架治疗方法
Trends Cardiovasc Med. 2003 May;13(4):142-8. doi: 10.1016/s1050-1738(03)00038-0.
4
Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy.血管损伤和支架置入后平滑肌细胞增殖和内皮再生的机制：治疗方法。
Circ J. 2011;75(6):1287-96. doi: 10.1253/circj.cj-11-0366. Epub 2011 Apr 29.
5
Stent thrombosis: nightmare of the interventional cardiology era.支架血栓形成：介入心脏病学时代的噩梦。
Int J Cardiol. 2011 May 5;148(3):e51-2. doi: 10.1016/j.ijcard.2009.03.002. Epub 2009 Mar 12.
6
Late coronary stent thrombosis.晚期冠状动脉支架内血栓形成
Circulation. 2007 Oct 23;116(17):1952-65. doi: 10.1161/CIRCULATIONAHA.106.683995.
7
[Restenosis after coronary angioplasty: pathomechanism and potential targets for therapeutic intervention. Focus on inflammation].[冠状动脉血管成形术后再狭窄：病理机制及治疗干预的潜在靶点。聚焦于炎症]
Postepy Hig Med Dosw (Online). 2007;61:58-73.
8
[The incidence and mechanism of restenosis after PTCA].[经皮腔内冠状动脉成形术后再狭窄的发生率及机制]
Nihon Rinsho. 1994 Jul;52 Suppl(Pt 1):856-62.
9
Coated stents for the prevention of restenosis: Part I.用于预防再狭窄的涂层支架：第一部分。
Circulation. 2002 Nov 19;106(21):2734-40. doi: 10.1161/01.cir.0000038982.49640.70.
10
Pathophysiology of coronary artery in-stent restenosis.冠状动脉支架内再狭窄的病理生理学
Acute Card Care. 2007;9(2):111-9. doi: 10.1080/17482940701263285.

引用本文的文献

1
Clinical and Inflammatory Outcomes of Rotational Atherectomy in Calcified Coronary Lesions: A Systematic Review and Meta-Analysis.钙化冠状动脉病变旋磨术的临床及炎症结局：一项系统评价与荟萃分析
J Clin Med. 2025 Jul 31;14(15):5389. doi: 10.3390/jcm14155389.
2
Evaluation of Ultrasonic Spray Method for Application of Sirolimus-Eluting Coating on Bioresorbable Vascular Scaffolds.用于在生物可吸收血管支架上涂覆西罗莫司洗脱涂层的超声喷涂方法的评估
Int J Mol Sci. 2025 Aug 7;26(15):7649. doi: 10.3390/ijms26157649.
3
Fortilin deficiency induces anti-atherosclerotic phenotypes in macrophages and protects hypercholesterolemic mice against atherosclerosis.凝溶胶蛋白缺乏诱导巨噬细胞产生抗动脉粥样硬化表型，并保护高胆固醇血症小鼠免受动脉粥样硬化影响。
Commun Biol. 2025 Jul 11;8(1):1040. doi: 10.1038/s42003-025-08425-w.
4
Survivin modulates stiffness-induced vascular smooth muscle cell motility.生存素调节硬度诱导的血管平滑肌细胞运动。
APL Bioeng. 2025 Jun 4;9(2):026120. doi: 10.1063/5.0252766. eCollection 2025 Jun.
5
NEXN regulates vascular smooth muscle cell phenotypic switching and neointimal hyperplasia.NEXN调节血管平滑肌细胞表型转换和内膜增生。
JCI Insight. 2025 May 29;10(13). doi: 10.1172/jci.insight.190089. eCollection 2025 Jul 8.
6
Finger blood flow (FBF) measurement among vibration-exposed groundskeepers: a pilot study in the southeastern USA.接触振动的场地管理员手指血流量（FBF）测量：美国东南部的一项初步研究。
Occup Environ Med. 2025 Apr 16;82(2):83-89. doi: 10.1136/oemed-2024-109979.
7
Microenvironment-responsive coating for vascular stents to regulate coagulation-inflammation interaction and promote vascular recovery.用于血管支架的微环境响应性涂层，以调节凝血-炎症相互作用并促进血管恢复。
Bioact Mater. 2025 Feb 26;48:443-457. doi: 10.1016/j.bioactmat.2025.02.031. eCollection 2025 Jun.
8
Targeted approach for next-generation coronary stents.下一代冠状动脉支架的靶向方法。
Eur Heart J. 2025 May 2;46(17):1659-1661. doi: 10.1093/eurheartj/ehaf007.
9
Inhibitory effects on smooth muscle cell adhesion and proliferation due to oscillating electric fields by nanogenerators.纳米发电机产生的振荡电场对平滑肌细胞黏附和增殖的抑制作用。
Nanoscale. 2025 Mar 24;17(12):7244-7252. doi: 10.1039/d4nr04405c.
10
Balloon expandable coronary stent materials: a systematic review focused on clinical success.球囊扩张型冠状动脉支架材料：一项聚焦于临床成功的系统评价
In Vitro Model. 2022 Jan 31;1(2):151-175. doi: 10.1007/s44164-022-00009-w. eCollection 2022 Apr.

本文引用的文献

1
In-stent restenosis.支架内再狭窄。
Cardiovasc Ther. 2011 Jun;29(3):190-8. doi: 10.1111/j.1755-5922.2010.00155.x. Epub 2010 Apr 9.
2
Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).在新发冠状动脉病变患者中，与紫杉醇洗脱支架相比，依维莫司洗脱支架的安全性、疗效和成本效益：来自 ENDEAVOR IV 试验的 2 年随访结果（美敦力 Endeavor 药物[ABT-578]洗脱冠状动脉支架系统与紫杉醇洗脱 Taxus 冠状动脉支架系统在新发原生冠状动脉病变中的随机对照试验）。
JACC Cardiovasc Interv. 2009 Dec;2(12):1208-18. doi: 10.1016/j.jcin.2009.10.008.
3
Progenitor cell-derived smooth muscle cells in vascular disease.血管疾病中的祖细胞衍生的平滑肌细胞。
Biochem Pharmacol. 2010 Jun 15;79(12):1706-13. doi: 10.1016/j.bcp.2010.01.027. Epub 2010 Feb 1.
4
Rapamycin regulates endothelial cell migration through regulation of the cyclin-dependent kinase inhibitor p27Kip1.雷帕霉素通过调节细胞周期蛋白依赖性激酶抑制剂 p27Kip1 调节内皮细胞迁移。
J Biol Chem. 2010 Apr 16;285(16):11991-7. doi: 10.1074/jbc.M109.066621. Epub 2010 Jan 22.
5
The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease.miR-143 和 -145 的敲除改变了小鼠平滑肌细胞的维持和血管内稳态：与人类疾病相关。
Cell Death Differ. 2009 Dec;16(12):1590-8. doi: 10.1038/cdd.2009.153. Epub 2009 Oct 9.
6
One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study.XIENCE V依维莫司洗脱支架系统治疗初发原生冠状动脉病变患者的一年临床随访：SPIRIT II研究
EuroIntervention. 2007 Nov;3(3):315-20. doi: 10.4244/eijv3i3a58.
7
MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury.微小RNA miR - 143和miR - 145调节细胞骨架动力学以及平滑肌细胞对损伤的反应性。
Genes Dev. 2009 Sep 15;23(18):2166-78. doi: 10.1101/gad.1842409. Epub 2009 Aug 31.
8
Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster.小鼠动脉平滑肌细胞收缩表型的获得取决于Mir143/145基因簇。
J Clin Invest. 2009 Sep;119(9):2634-47. doi: 10.1172/JCI38864. Epub 2009 Aug 17.
9
MicroRNA-modulated targeting of vascular smooth muscle cells.微小RNA对血管平滑肌细胞的靶向调控
J Clin Invest. 2009 Sep;119(9):2526-8. doi: 10.1172/JCI40503. Epub 2009 Aug 17.
10
miR-145 and miR-143 regulate smooth muscle cell fate and plasticity.微小RNA-145和微小RNA-143调控平滑肌细胞的命运和可塑性。
Nature. 2009 Aug 6;460(7256):705-10. doi: 10.1038/nature08195. Epub 2009 Jul 5.